FDA puts hold on Phase II anthrax vaccine trial

The FDA has put a clinical hold on VaxGen's next Phase II trial for its troubled anthrax vaccine, "because data submitted to date by the company are insufficient to determine that the product is stable enough to resume clinical testing." In the notification, VaxGen added, the agency expressed concerns that the vaccine's potency could decline during the immunization phase of the trial, potentially resulting in an uninterpretable outcome. 

VaxGen has run into repeated trouble with the FDA over its anthrax vaccine. The agency has accused VaxGen of making exaggerated claims about the vaccine and threatened court action this year in an effort to make the company shape up. And the Washington Post reported last spring that trouble in developing the vaccine was delaying delivery past an agreed November deadline.

- here's the release on VaxGen

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.